Hepatitis C Treatment: A Review and Update.

  • Jelena Jakab* Faculty of Medicine, Josip JurajStrossmayerUniversity of Osijek, Osijek, Croatia
  • Marinko Žulj Faculty of Medicine, Josip JurajStrossmayerUniversity of Osijek, Osijek, Croatia
  • Nikola Volarić Faculty of Medicine, Josip JurajStrossmayerUniversity of Osijek, Osijek, Croatia
  • Bojan Tepes Diagnostic Center Rogaska, Rogaska Slatina, Slovenia
  • Aleksandar Včev Faculty of Medicine, Josip JurajStrossmayerUniversity of Osijek, Osijek, Croatia

Abstract

Hepatitis C virus infection (HCV) infects approximately 185 million individuals worldwide. It is a leading cause of chronic liver disease and the primary reason for liver transplantation. The main aim of antiviral treatment is to achieve a sustained virologic response, which means eradication of the virus. The combination of pegylated-interferon and ribavirin was the standard of care for over a decade, despite the long treatment duration and severe adverse effects. The introduction of direct-acting antivirals with pan-genomic properties and excellent tolerance increased rates of SVR and shortened the duration of the therapy. Furthermore, it allowed clinicians to customise HCV therapy according to important clinical parameters such as HCV- genotype and liver fibrosis stage.

Published
Apr 25, 2017
How to Cite
JAKAB*, Jelena et al. Hepatitis C Treatment: A Review and Update.. Southeastern European Medical Journal, [S.l.], v. 1, n. 1, p. 11-18, apr. 2017. ISSN 2459-9484. Available at: <http://seemedj.mefos.unios.hr/index.php/seemedj/article/view/27>. Date accessed: 17 nov. 2017.